Company: HRTX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-028374
Chunk: 181

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 181
---
 purchases under the Employee Stock Purchase Plan

    637

    904

    1,444

    Receipts (payments) for stock issued under the equity incentive plan

    303

    (903
    )

    (1,530
    )

    Proceeds from warrant exercises

    —

    1

    —

    Net cash provided by financing activities

    940

    54,107

    75,059

    Net (decrease) increase in cash and cash equivalents

    (2,875
    )

    13,313

    (75,177
    )

    Cash and cash equivalents at beginning of year

    28,677

    15,364

    90,541

    Cash and cash equivalents at end of year
     
    $
    25,802

    $
    28,677

    $
    15,364

    Supplemental disclosure of cash flow information:

    Interest paid
     
    $
    4,860

    $
    3,059

    $
    2,250

See accompanying Notes to Consolidated Financial Statements.

77

HERON THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.Organization and BusinessWe are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.ZYNRELEF® (bupivacaine and meloxicam) extended-release solution (“ZYNRELEF”) is approved in the United States (“U.S.”) for the management of postoperative pain. APONVIE® (aprepitant) injectable emulsion (“APONVIE”) is approved in the U.S. for the prevention of postoperative nausea and vomiting. CINVANTI® (aprepitant) injectable emulsion (“CINVANTI”) and SUSTOL® (granisetron) extended-release injection (“SUSTOL”) are both approved in the U.S. for the prevention of chemotherapy-induced nausea and vomiting.As of December 31, 2024, we had cash, cash equivalents, and short-term investments of $59.3 million. Based on our current operating plan and projections, management believes